Program
opakalim
Its studies are mostly in Epilepsies, Partial · Depressive Disorder, Major · Bipolar Disorder · Neuralgia · Epilepsy, Idiopathic Generalized, led by Biohaven Therapeutics.
Furthest: phase 3, since Nov 10, 20239 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biohaven Therapeutics | 94 open or running | phase 3since Nov 10, 2023 | Nov 10, 2023 | Dec 2026phase 3 · NCT06132893 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 10, 2023First study: phase 3 study in Epilepsies, PartialFirst studyNCT06132893 · 390 enrolled · United States, Argentina, Austria and more
- Mar 8, 2024Phase 3 study in Epilepsies, PartialNCT06309966 · 390 enrolled · United States, Australia, Denmark and more
- May 14, 20244 phase 2 studiesNCT06419608, NCT06423794, NCT06423781 and 1 more
- May 14, 20242 phase 3 studiesNCT06419582, NCT06425159
- Nov 17, 2025Phase 1 study in ErythromelalgiaNCT07262268 · 5 enrolled · United States
Ahead
- Dec 2026Primary completion: phase 2 study in Epilepsies, PartialNCT06443463
- Dec 2026Primary completion: phase 3 study in Epilepsies, PartialNCT06132893
- Nov 2027Primary completion: phase 1 study in ErythromelalgiaNCT07262268
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07262268Erythromelalgia · United States | 1 | Active, not recruiting | Nov 2027 | 5 |
| NCT06443463Epilepsies, Partial · United States, Argentina, Australia and more | 2 | By invitation | Dec 2026 | 660 |
| NCT06425159Epilepsy, Generalized · United States, Australia, Austria and more | 3 | Terminated | Mar 12, 2026 | 27 |
| NCT06423794Bipolar Disorder · United States | 2 | Terminated | Apr 25, 2025 | 94 |
| NCT06423781Depressive Disorder, Major · United States | 2 | Completed | Mar 18, 2026 | 233 |
| NCT06419608Depressive Disorder, Major · United States | 2 | Completed | Nov 7, 2025 | 336 |
| NCT06419582Bipolar Disorder · United States | 3 | Completed | Jan 15, 2025 | 274 |
| NCT06309966Epilepsies, Partial · United States, Australia, Denmark and more | 3 | Active, not recruiting | Oct 2026 | 390 |
| NCT06132893Epilepsies, Partial · United States, Argentina, Austria and more | 3 | Active, not recruiting | Dec 2026 | 390 |
How it is read
Names in the registry
- “BHV-7000”, 13 entries
Conditions, from the studies’ own filings
- Epilepsies, Partial, 3 studies
- Depressive Disorder, Major, 2 studies
- Bipolar Disorder, 2 studies
- Neuralgia, 1 study
- Epilepsy, Idiopathic Generalized, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.